| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| MNKD | MNKD | Shares | USD | XNMS |
| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| MNKD | MNKD | Shares | USD | XNMS |
MannKind Corporation develops treatments for serious medical conditions, focusing on diabetes and cardiometabolic diseases. Its primary product is Afrezza®, an ultra rapid-acting inhaled insulin that utilizes Technosphere® technology. The company also offers Furoscix ReadyFlow™, which allows patients to manage fluid buildup at home. MannKind operates in the biopharmaceutical sector, targeting patients with diabetes and orphan lung diseases.
No recent RNS announcements for MNKD across MNKD.
No recent RNS announcements for MNKD across MNKD.